ACADIA Pharmaceuticals Inc (ACAD) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Total Assets Chart for ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc (ACAD) total assets for FY2025 were USD 1.6B, a 31.7% change from FY2024. ACADIA Pharmaceuticals Inc's total assets grew from USD 34.1M in 2000 to USD 1.6B in 2025 (4485.3% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 14.9%, 10-year CAGR of 21.6%, 20-year CAGR of 17.5%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.39B
- Implied Share Price
- $19.80
- Enterprise Value
- $3.50B
- Revenue (TTM)
- $1.14B
- EBITDA
- $98.39M
- Profit Margin
- 33.42%
- Trailing P/E
- 8.57
- Forward P/E
- 25.19
- Price/Book (MRQ)
- 3.35
- Price/Sales (TTM)
- 3.00
- EV/EBITDA
- 35.53
- EV/Revenue
- 3.07
- Dividend Yield
- —
- Book Value
- $7.59
- Free Cash Flow (FY2025)
- $105.15M
- Free Cash Flow Yield
- 3.10%
Snapshot as of 20th October 2026 — not point-in-time controlled, may lag the live market by a few days.